Glaucoma Surgery Devices-Medical Devices Pipeline Assessment, 2017

Region:Global

Author(s):

Product Code:GDME0398EPD

Download Sample Report download
Buy the Full ReportStarting from $4000
Published on

August 2017

Total pages

192

Table of Content

Download Sample Report download
Buy the Full ReportStarting from $4000

About the Report

About the Report

Glaucoma Surgery Devices-Medical Devices Pipeline Assessment, 2017

Summary

GlobalData's Medical Devices sector report, "Glaucoma Surgery Devices-Medical Devices Pipeline Assessment, 2017" provides an overview of Glaucoma Surgery Devices currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Glaucoma Surgery Devices pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

Extensive coverage of the Glaucoma Surgery Devices under development

The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities

The report reviews the major players involved in the development of Glaucoma Surgery Devices and list all their pipeline projects

The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage

The report provides key clinical trial data of ongoing trials specific to pipeline products

Recent developments in the segment / industry

Reasons to buy

The report enables you to-

Formulate significant competitor information, analysis, and insights to improve R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of Glaucoma Surgery Devices under development

Develop market-entry and market expansion strategies

Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline

In-depth analysis of the product's current stage of development, territory and estimated launch date

Products

Products

Anteis SA, Drainage Viscoelastic Injectable Implant; Assenti, LLC, Intraocular Pressure Monitoring System; Camras Vision, Camras Shunt; Ellex Medical Lasers Limited, Glaucoma Device; Eye Sonix, Therapeutic Ultrasound Device-Glaucoma; Galaxy Ophthalmics Inc, Titan Shunt; Geuder AG, MikroAug; Glaukos Corp, GTS400; Glaukos Corp, iStent Inject-Cataract Surgery; Glaukos Corp, iStent Inject-Standalone Procedures; Glaukos Corp, iStent Supra Suprachoroidal Micro-Bypass Stent; iSTAR Medical SA, MINIject; iSTAR Medical SA, STARflo MINI; iSTAR Medical SA, STARflo Plus Glaucoma Implant; Ivantis Inc, Hydrus Microstent; iVeena Delivery Systems Inc, IVMED-70; Kytogenics Pharmaceuticals Inc, MACC-Based Device-Glaucoma Filtering; Massachusetts Eye and Ear Infirmary, Pressure Relief Valve Shunt; Medtronic plc, CellPlant; Meir Medical Center, Glaucoma Drainage Device; MicroOptx, Inc., Brown Glaucoma Implant (BGI); Oculox Technology Sagl, Intraocular Piezoresistive Pressure Sensor; Ocumatrx, CaPRI Device; OcuTherix Inc, Deep Wave Trabeculoplasty Device; OPKO Health Inc, Aquashunt; OptoLight Vision Technology, Lipshitz Macular Implant For Advanced Glaucoma; PolyActiva Pty Ltd, Fully Bioerodible Ocular Implant-Glaucoma; Queen's University, Laser Adjustable Suture; Santen Pharmaceutical Co Ltd, InnFocus Microshunt; Sheba Medical Center, Toroidal Glaucoma Drainage Device; Sight Sciences, Inc., VISCO 360 Viscosurgical System-Primary Open Angle Glaucoma; SOLX Inc, SOLX Gold Shunt; Tel Aviv University, Direct Laser Trabeculoplasty System; Tel Aviv University, Glaucoma Implant; TonoGuard Ltd., EasyIOP; University of Colorado, Aqueous Humor Micro-Bypass Shunt; University of Colorado, Glaucoma Device; University of Michigan, Magnetoelastic Actuator; University of Rostock, PTX-Eluting Microstent; ViSci Ltd, Eye-D; Westhouse Medical Services Plc, Pneumatic Trabeculoplasty System


Companies

Anteis SA

Assenti, LLC

Camras Vision

Ellex Medical Lasers Limited

Eye Sonix

Galaxy Ophthalmics Inc

Geuder AG

Glaukos Corp

iSTAR Medical SA

Ivantis Inc

iVeena Delivery Systems Inc

Kytogenics Pharmaceuticals Inc

Massachusetts Eye and Ear Infirmary

Medtronic plc

Meir Medical Center

MicroOptx, Inc.

Oculox Technology Sagl

Ocumatrx

OcuTherix Inc

OPKO Health Inc

OptoLight Vision Technology

PolyActiva Pty Ltd

Queen's University

Santen Pharmaceutical Co Ltd

Sheba Medical Center

Sight Sciences, Inc.

SOLX Inc

Tel Aviv University

TonoGuard Ltd.

University of Colorado

University of Michigan

University of Rostock

ViSci Ltd

Westhouse Medical Services Plc

Table of Contents

Table of Contents

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 7

1.2 List of Figures 10

2 Introduction 11

2.1 Glaucoma Surgery Devices Overview 11

3 Products under Development 12

3.1 Glaucoma Surgery Devices-Pipeline Products by Stage of Development 12

3.2 Glaucoma Surgery Devices-Pipeline Products by Segment 13

3.3 Glaucoma Surgery Devices-Pipeline Products by Territory 14

3.4 Glaucoma Surgery Devices-Pipeline Products by Regulatory Path 15

3.5 Glaucoma Surgery Devices-Pipeline Products by Estimated Approval Date 16

3.6 Glaucoma Surgery Devices-Ongoing Clinical Trials 17

4 Glaucoma Surgery Devices-Pipeline Products under Development by Companies 18

4.1 Glaucoma Surgery Devices Companies-Pipeline Products by Stage of Development 18

4.2 Glaucoma Surgery Devices-Pipeline Products by Stage of Development 20

5 Glaucoma Surgery Devices Companies and Product Overview 22

5.1 Anteis SA Company Overview 22

5.1.1 Anteis SA Pipeline Products & Ongoing Clinical Trials Overview 22

5.2 Assenti, LLC Company Overview 23

5.2.1 Assenti, LLC Pipeline Products & Ongoing Clinical Trials Overview 23

5.3 Camras Vision Company Overview 24

5.3.1 Camras Vision Pipeline Products & Ongoing Clinical Trials Overview 24

5.4 Ellex Medical Lasers Limited Company Overview 25

5.4.1 Ellex Medical Lasers Limited Pipeline Products & Ongoing Clinical Trials Overview 25

5.5 Eye Sonix Company Overview 26

5.5.1 Eye Sonix Pipeline Products & Ongoing Clinical Trials Overview 26

5.6 Galaxy Ophthalmics Inc Company Overview 27

5.6.1 Galaxy Ophthalmics Inc Pipeline Products & Ongoing Clinical Trials Overview 27

5.7 Geuder AG Company Overview 28

5.7.1 Geuder AG Pipeline Products & Ongoing Clinical Trials Overview 28

5.8 Glaukos Corp Company Overview 29

5.8.1 Glaukos Corp Pipeline Products & Ongoing Clinical Trials Overview 29

5.9 iSTAR Medical SA Company Overview 37

5.9.1 iSTAR Medical SA Pipeline Products & Ongoing Clinical Trials Overview 37

5.10 Ivantis Inc Company Overview 41

5.10.1 Ivantis Inc Pipeline Products & Ongoing Clinical Trials Overview 41

5.11 iVeena Delivery Systems Inc Company Overview 45

5.11.1 iVeena Delivery Systems Inc Pipeline Products & Ongoing Clinical Trials Overview 45

5.12 Kytogenics Pharmaceuticals Inc Company Overview 46

5.12.1 Kytogenics Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 46

5.13 Massachusetts Eye and Ear Infirmary Company Overview 47

5.13.1 Massachusetts Eye and Ear Infirmary Pipeline Products & Ongoing Clinical Trials Overview 47

5.14 Medtronic plc Company Overview 48

5.14.1 Medtronic plc Pipeline Products & Ongoing Clinical Trials Overview 48

5.15 Meir Medical Center Company Overview 49

5.15.1 Meir Medical Center Pipeline Products & Ongoing Clinical Trials Overview 49

5.16 MicroOptx, Inc. Company Overview 50

5.16.1 MicroOptx, Inc. Pipeline Products & Ongoing Clinical Trials Overview 50

5.17 Oculox Technology Sagl Company Overview 51

5.17.1 Oculox Technology Sagl Pipeline Products & Ongoing Clinical Trials Overview 51

5.18 Ocumatrx Company Overview 52

5.18.1 Ocumatrx Pipeline Products & Ongoing Clinical Trials Overview 52

5.19 OcuTherix Inc Company Overview 53

5.19.1 OcuTherix Inc Pipeline Products & Ongoing Clinical Trials Overview 53

5.20 OPKO Health Inc Company Overview 54

5.20.1 OPKO Health Inc Pipeline Products & Ongoing Clinical Trials Overview 54

5.21 OptoLight Vision Technology Company Overview 55

5.21.1 OptoLight Vision Technology Pipeline Products & Ongoing Clinical Trials Overview 55

5.22 PolyActiva Pty Ltd Company Overview 56

5.22.1 PolyActiva Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview 56

5.23 Queen's University Company Overview 57

5.23.1 Queen's University Pipeline Products & Ongoing Clinical Trials Overview 57

5.24 Santen Pharmaceutical Co Ltd Company Overview 58

5.24.1 Santen Pharmaceutical Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 58

5.25 Sheba Medical Center Company Overview 61

5.25.1 Sheba Medical Center Pipeline Products & Ongoing Clinical Trials Overview 61

5.26 Sight Sciences, Inc. Company Overview 62

5.26.1 Sight Sciences, Inc. Pipeline Products & Ongoing Clinical Trials Overview 62

5.27 SOLX Inc Company Overview 65

5.27.1 SOLX Inc Pipeline Products & Ongoing Clinical Trials Overview 65

5.28 Tel Aviv University Company Overview 66

5.28.1 Tel Aviv University Pipeline Products & Ongoing Clinical Trials Overview 66

5.29 TonoGuard Ltd. Company Overview 68

5.29.1 TonoGuard Ltd. Pipeline Products & Ongoing Clinical Trials Overview 68

5.30 University of Colorado Company Overview 69

5.30.1 University of Colorado Pipeline Products & Ongoing Clinical Trials Overview 69

5.31 University of Michigan Company Overview 71

5.31.1 University of Michigan Pipeline Products & Ongoing Clinical Trials Overview 71

5.32 University of Rostock Company Overview 72

5.32.1 University of Rostock Pipeline Products & Ongoing Clinical Trials Overview 72

5.33 ViSci Ltd Company Overview 73

5.33.1 ViSci Ltd Pipeline Products & Ongoing Clinical Trials Overview 73

5.34 Westhouse Medical Services Plc Company Overview 74

5.34.1 Westhouse Medical Services Plc Pipeline Products & Ongoing Clinical Trials Overview 74

6 Glaucoma Surgery Devices-Recent Developments 75

6.1 Jul 24, 2017: BioLight Reports Successful Results in Phase 1/2a Clinical Trial for Glaucoma Insert 75

6.2 Jul 19, 2017: Joseph H. Boccuzi Appointed to Allergan Board of Directors 76

6.3 Jul 06, 2017: Ellex Medical Lasers: Trading Update for the Year Ended 30 June 2017 76

6.4 Jun 26, 2017: Ocular Therapeutix Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) 78

6.5 Jun 22, 2017: Ocular Therapeutix Announces Executive Transition Plans 78

6.6 Jun 22, 2017: Ellex iTrack Sales and Marketing Activities 79

6.7 Jun 21, 2017: Combining Implantation of Glaukos iStent inject Trabecular Micro-Bypass with Topical Travoprost Provides Sustained IOP Reduction and Favorable Safety Profile, According to New Study 80

6.8 Jun 21, 2017: Combining Implantation of Glaukos iStent inject Trabecular Micro-Bypass with Topical Travoprost Provides Sustained IOP Reduction and Favorable Safety Profile, According to New Study 82

6.9 May 25, 2017: Medtronic Reports Fourth Quarter and Fiscal Year 2017 Financial Results 83

6.10 May 22, 2017: Study Reveals Potential Cost Efficiency of Using Two Glaukos iStent Trabecular Micro-Bypass Stents to Treat Elevated IOP in Glaucoma Patients 86

6.11 May 09, 2017: OPKO Health Reports 2016 Financial and Operating Results 87

6.12 May 09, 2017: Allergan Reports Solid Start to 2017 with 5% Increase in First Quarter GAAP Net Revenues to $3.6 Billion 88

6.13 May 05, 2017: Ellex iTrack MIGS Technology to Feature at 2017 American Society of Cataract and Refractive Surgery 93

6.14 May 05, 2017: Ocular Therapeutix Reports First Quarter 2017 Financial Results 95

6.15 May 03, 2017: Glaukos Announces First Quarter 2017 Financial Results 97

6.16 May 03, 2017: STAAR Surgical Reports First Quarter 2017 Results 98

6.17 May 02, 2017: Several Surgeon Presentations to Include Glaukos Technologies at 2017 American Society of Cataract and Refractive Surgery 99

6.18 May 01, 2017: Several Surgeon Presentations to Include Glaukos Technologies at 2017 American Society of Cataract and Refractive Surgery 101

6.19 Apr 26, 2017: Alcon announces EU launch of CyPass Micro-Stent, a micro invasive glaucoma surgical device, to lower intraocular pressure (IOP) in patients with primary open-angle glaucoma 104

6.20 Apr 25, 2017: Ivantis Announces FDA Clearance to Initiate Clinical Trial of the Hydrus Microstent for Minimally Invasive Glaucoma Surgery (MIGS) in Patients with Advanced Glaucoma 105

6.21 Apr 19, 2017: Jeffrey Peterson, M.D. first in Hawaii to use new glaucoma surgery device 106

6.22 Apr 13, 2017: International Study Shows Two Glaukos iStent Trabecular Micro-Bypass Stents and One Topical Medication Deliver Sustained IOP Reduction 107

6.23 Apr 13, 2017: Sight Sciences Announces Health Canada Approval of the VISCO 360 Viscosurgical System for Standalone Microinvasive Glaucoma Surgery 108

6.24 Apr 10, 2017: Allergan Receives 2017 ENERGY STAR Partner of the Year-Sustained Excellence Award from U.S. Environmental Protection Agency 109

6.25 Apr 06, 2017: Allergan Names Daphne Karydas as Senior Vice President of Global Investor Relations & Strategy 110

6.26 Apr 06, 2017: Ocular Therapeutix Appoints George Migausky as Interim Chief Financial Officer 110

6.27 Apr 05, 2017: STAAR Surgical Names Deborah Andrews Interim CFO 111

6.28 Mar 22, 2017: Vance Thompson Vision first to use CyPass Micro-Stent in the area 111

6.29 Mar 16, 2017: Glaukos Announces Five-Year Extensions For Three Category III CPT Codes Related To Micro-Invasive Glaucoma Surgery 112

6.30 Mar 14, 2017: USC Roski Eye Institute ophthalmologists are first to use XEN gel stent to treat glaucoma patients in Los Angeles 113

6.31 Mar 10, 2017: Ocular Therapeutix Reports Fourth Quarter and Full Year 2016 Financial Results 114

6.32 Mar 03, 2017: OPKO Health Appoints Dr. Akhtar Ashfaq as Renal Division Senior Vice President, Clinical Research and Development 116

6.33 Mar 02, 2017: STAAR Surgical Reports Fourth Quarter 2016 Results 117

6.34 Mar 01, 2017: OPKO Health Reports 2016 Financial and Operating Results 118

6.35 Mar 01, 2017: Glaukos Announces Fourth Quarter & Full Year 2016 Financial Results 119

6.36 Feb 28, 2017: Glaukos Technologies Featured in Eight Presentations at 2017 American Glaucoma Society Meeting 121

6.37 Feb 28, 2017: IRIDEX Launches New FDA-Cleared Probe At The Annual American Glaucoma Society Meeting 122

6.38 Feb 27, 2017: Lisa DeFrancesco, Vice President of Investor Relations, to Leave Allergan 123

6.39 Feb 27, 2017: Ellex Medical Lasers: Financial Report for Half-Year Ended 31 December 2016 123

6.40 Feb 22, 2017: Preeminent Ophthalmologist, L. Jay Katz Joins Glaukos as Chief Medical Officer 124

6.41 Feb 21, 2017: Medtronic Reports Third Quarter Financial Results 125

6.42 Feb 16, 2017: Glaukos Completes Patient Enrollment in Pivotal Phase of U.S. IDE Clinical Trial for iStent SUPRA 128

6.43 Feb 15, 2017: Sight Sciences Announces Expanding Management Team of Seasoned Medical Device Experts 129

6.44 Feb 08, 2017: Allergan Reports Strong 2016 Finish with 7% Increase in GAAP Net Revenues to $3.9 Billion in Fourth Quarter 2016 130

6.45 Feb 06, 2017: Medtronic Awarded U.S. Department of Veterans Affairs National Contracts for Home Telehealth Technologies, with Three Other Vendors 135

6.46 Feb 06, 2017: Joseph Gilliam to Join Glaukos Corporation as Chief Financial Officer and Senior Vice President of Corporate Development 136

6.47 Feb 02, 2017: Ellex Trading Update for the Six Months Ended 31 December 2016 136

6.48 Feb 01, 2017: Glaukos Promotes Chris M. Calcaterra to Chief Operating Officer 138

6.49 Jan 05, 2017: Allergan to Present at Goldman Sachs Healthcare CEOs Unscripted Conference and Provides Preliminary Comments on 2017 Outlook 139

7 Appendix 189

7.1 Methodology 189

7.2 About GlobalData 192

7.3 Contact Us 192

7.4 Disclaimer 192


List of Figure

1.2 List of Figures

Figure 1: Glaucoma Surgery Devices-Pipeline Products by Stage of Development 12

Figure 2: Glaucoma Surgery Devices-Pipeline Products by Segment 13

Figure 3: Glaucoma Surgery Devices-Pipeline Products by Territory 14

Figure 4: Glaucoma Surgery Devices-Pipeline Products by Regulatory Path 15

Figure 5: Glaucoma Surgery Devices-Pipeline Products by Estimated Approval Date 16

Figure 6: Glaucoma Surgery Devices-Ongoing Clinical Trials 17


List of Table

1.1 List of Tables

Table 1: Glaucoma Surgery Devices-Pipeline Products by Stage of Development 12

Table 2: Glaucoma Surgery Devices-Pipeline Products by Segment 13

Table 3: Glaucoma Surgery Devices-Pipeline Products by Territory 14

Table 4: Glaucoma Surgery Devices-Pipeline Products by Regulatory Path 15

Table 5: Glaucoma Surgery Devices-Pipeline Products by Estimated Approval Date 16

Table 6: Glaucoma Surgery Devices-Ongoing Clinical Trials 17

Table 7: Glaucoma Surgery Devices Companies-Pipeline Products by Stage of Development 18

Table 8: Glaucoma Surgery Devices-Pipeline Products by Stage of Development 20

Table 9: Anteis SA Pipeline Products & Ongoing Clinical Trials Overview 22

Table 10: Drainage Viscoelastic Injectable Implant-Product Status 22

Table 11: Drainage Viscoelastic Injectable Implant-Product Description 22

Table 12: Assenti, LLC Pipeline Products & Ongoing Clinical Trials Overview 23

Table 13: Intraocular Pressure Monitoring System-Product Status 23

Table 14: Intraocular Pressure Monitoring System-Product Description 23

Table 15: Camras Vision Pipeline Products & Ongoing Clinical Trials Overview 24

Table 16: Camras Shunt-Product Status 24

Table 17: Camras Shunt-Product Description 24

Table 18: Ellex Medical Lasers Limited Pipeline Products & Ongoing Clinical Trials Overview 25

Table 19: Glaucoma Device-Product Status 25

Table 20: Glaucoma Device-Product Description 25

Table 21: Eye Sonix Pipeline Products & Ongoing Clinical Trials Overview 26

Table 22: Therapeutic Ultrasound Device-Glaucoma-Product Status 26

Table 23: Therapeutic Ultrasound Device-Glaucoma-Product Description 26

Table 24: Galaxy Ophthalmics Inc Pipeline Products & Ongoing Clinical Trials Overview 27

Table 25: Titan Shunt-Product Status 27

Table 26: Titan Shunt-Product Description 27

Table 27: Geuder AG Pipeline Products & Ongoing Clinical Trials Overview 28

Table 28: MikroAug-Product Status 28

Table 29: MikroAug-Product Description 28

Table 30: Glaukos Corp Pipeline Products & Ongoing Clinical Trials Overview 29

Table 31: GTS400-Product Status 29

Table 32: GTS400-Product Description 29

Table 33: iStent Inject-Cataract Surgery-Product Status 30

Table 34: iStent Inject-Cataract Surgery-Product Description 30

Table 35: iStent Inject-Standalone Procedures-Product Status 30

Table 36: iStent Inject-Standalone Procedures-Product Description 31

Table 37: iStent Supra Suprachoroidal Micro-Bypass Stent-Product Status 31

Table 38: iStent Supra Suprachoroidal Micro-Bypass Stent-Product Description 31

Table 39: Glaukos Corp-Ongoing Clinical Trials Overview 32

Table 40: iStent Supra Suprachoroidal Micro-Bypass Stent-A Prospective Evaluation of Mild to Moderate Open-angle Glaucoma Subjects Treated with Second Generationtrabecular Micro-bypass Stents and One Suprachoroidal Stent a Multicenter Study According to Mpg §23.B 33

Table 41: iStent Supra Suprachoroidal Micro-Bypass Stent-A Prospective Evaluation of Open-angle Glaucoma Subjects on Two Topical Hypotensive Medication Treated with One Suprachoroidal Stent 33

Table 42: iStent Supra Suprachoroidal Micro-Bypass Stent-A Prospective Evaluation of Open-angle Glaucoma Subjects with One Prior Trabeculectomy Treated Concurrently with One Suprachoroidal Stent and Two Trabecular Micro-bypass Stents and a Postoperative Prostaglandin 33

Table 43: iStent Supra Suprachoroidal Micro-Bypass Stent-A Prospective, Randomized, Single-masked, Controlled, Parallel Groups, Multicenter Clinical Investigation of the Glaukos Suprachoroidal Stent Model G3 in Conjunction with Cataract Surgery 34

Table 44: iStent Inject-Cataract Surgery-A Prospective, Randomized Evaluation of Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent Inject) or Travoprost Ophthalmic Solution 0.004% 35

Table 45: iStent Inject-Cataract Surgery-A Prospective, Randomized, Single-masked, Controlled, Parallel Groups, Multicenter Clinical Investigation of the Glaukos Trabecular Micro-Bypass Stent Model GTS400 Using the G2-M-IS Injector System in Conjunction with Cataract Surgery 35

Table 46: iStent Inject-Cataract Surgery-A Randomized Controlled Trial of Cataract Surgery Versus Combined Cataract Surgery with Insertion of iStent Inject 35

Table 47: iStent Inject-Standalone Procedures-A Prospective Evaluation of Mild to Moderate Open-angle Glaucoma Subjects Treated with Second Generationtrabecular Micro-bypass Stents and One Suprachoroidal Stent a Multicenter Study According to Mpg §23.B 36

Table 48: iStent Inject-Standalone Procedures-Initial Phase of U.S. IDE Clinical Trial for Standalone Version of iStent inject 36

Table 49: iStent Inject-Standalone Procedures-The Effect of Glaucoma Surgery on Aqueous Dynamics in Patients With Glaucoma or Ocular Hypertension: An Observational Study 36

Table 50: iSTAR Medical SA Pipeline Products & Ongoing Clinical Trials Overview 37

Table 51: MINIject-Product Status 37

Table 52: MINIject-Product Description 37

Table 53: STARflo MINI-Product Status 38

Table 54: STARflo MINI-Product Description 38

Table 55: STARflo Plus Glaucoma Implant-Product Status 38

Table 56: STARflo Plus Glaucoma Implant-Product Description 38

Table 57: iSTAR Medical SA-Ongoing Clinical Trials Overview 39

Table 58: MINIject-A Prospective, Open, Multicenter Clinical Trial with One Cohort Analysing the Efficacy and Safety of MINIject in Patients with Open Angle Glaucoma Uncontrolled by Topical Hypotensive Medications 40

Table 59: Ivantis Inc Pipeline Products & Ongoing Clinical Trials Overview 41

Table 60: Hydrus Microstent-Product Status 41

Table 61: Hydrus Microstent-Product Description 41

Table 62: Ivantis Inc-Ongoing Clinical Trials Overview 42

Table 63: Hydrus Microstent-A Prospective, Multicenter, Randomized Comparison of the Hydrus Microstent to the iStent for Lowering Intraocular Pressure in Glaucoma Patients Undergoing Cataract Surgery 43

Table 64: Hydrus Microstent-Evaluation of Safety and Efficacy of the Hydrus Microstent in Treatment of Patients with Advanced Glaucoma 43

Table 65: Hydrus Microstent-The Effect of Glaucoma Surgery on Aqueous Dynamics in Patients With Glaucoma or Ocular Hypertension: An Observational Study 43

Table 66: Hydrus Microstent-The Safety and Effectiveness of the Hydrus Aqueous Implant for Lowering Intraocular Pressure in Glaucoma Patients Undergoing Cataract Surgery, A Prospective, Multicenter, Randomized, Controlled Clinical Trial 43

Table 67: iVeena Delivery Systems Inc Pipeline Products & Ongoing Clinical Trials Overview 45

Table 68: IVMED-70-Product Status 45

Table 69: IVMED-70-Product Description 45

Table 70: Kytogenics Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 46

Table 71: MACC-Based Device-Glaucoma Filtering-Product Status 46

Table 72: MACC-Based Device-Glaucoma Filtering-Product Description 46

Table 73: Massachusetts Eye and Ear Infirmary Pipeline Products & Ongoing Clinical Trials Overview 47

Table 74: Pressure Relief Valve Shunt-Product Status 47

Table 75: Pressure Relief Valve Shunt-Product Description 47

Table 76: Medtronic plc Pipeline Products & Ongoing Clinical Trials Overview 48

Table 77: CellPlant-Product Status 48

Table 78: CellPlant-Product Description 48

Table 79: Meir Medical Center Pipeline Products & Ongoing Clinical Trials Overview 49

Table 80: Glaucoma Drainage Device-Product Status 49

Table 81: Glaucoma Drainage Device-Product Description 49

Table 82: MicroOptx, Inc. Pipeline Products & Ongoing Clinical Trials Overview 50

Table 83: Brown Glaucoma Implant (BGI)-Product Status 50

Table 84: Brown Glaucoma Implant (BGI)-Product Description 50

Table 85: Oculox Technology Sagl Pipeline Products & Ongoing Clinical Trials Overview 51

Table 86: Intraocular Piezoresistive Pressure Sensor-Product Status 51

Table 87: Intraocular Piezoresistive Pressure Sensor-Product Description 51

Table 88: Ocumatrx Pipeline Products & Ongoing Clinical Trials Overview 52

Table 89: CaPRI Device-Product Status 52

Table 90: CaPRI Device-Product Description 52

Table 91: OcuTherix Inc Pipeline Products & Ongoing Clinical Trials Overview 53

Table 92: Deep Wave Trabeculoplasty Device-Product Status 53

Table 93: Deep Wave Trabeculoplasty Device-Product Description 53

Table 94: OPKO Health Inc Pipeline Products & Ongoing Clinical Trials Overview 54

Table 95: Aquashunt-Product Status 54

Table 96: Aquashunt-Product Description 54

Table 97: OptoLight Vision Technology Pipeline Products & Ongoing Clinical Trials Overview 55

Table 98: Lipshitz Macular Implant For Advanced Glaucoma-Product Status 55

Table 99: Lipshitz Macular Implant For Advanced Glaucoma-Product Description 55

Table 100: PolyActiva Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview 56

Table 101: Fully Bioerodible Ocular Implant-Glaucoma-Product Status 56

Table 102: Fully Bioerodible Ocular Implant-Glaucoma-Product Description 56

Table 103: Queen's University Pipeline Products & Ongoing Clinical Trials Overview 57

Table 104: Laser Adjustable Suture-Product Status 57

Table 105: Laser Adjustable Suture-Product Description 57

Table 106: Santen Pharmaceutical Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 58

Table 107: InnFocus Microshunt-Product Status 58

Table 108: InnFocus Microshunt-Product Description 58

Table 109: Santen Pharmaceutical Co Ltd-Ongoing Clinical Trials Overview 59

Table 110: InnFocus Microshunt-A Randomized Study Comparing the Safety and Efficacy of the InnFocus MicroShunt Glaucoma Drainage System to Standard Trabeculectomy In Subjects with Primary Open Angle Glaucoma 60

Table 111: InnFocus Microshunt-Post Market Study to Evaluate Safety and Effectiveness of the InnFocus Microshunt (MIDI Arrow) in Patients with Primary Open Angle Glaucoma 60

Table 112: Sheba Medical Center Pipeline Products & Ongoing Clinical Trials Overview 61

Table 113: Toroidal Glaucoma Drainage Device-Product Status 61

Table 114: Toroidal Glaucoma Drainage Device-Product Description 61

Table 115: Sight Sciences, Inc. Pipeline Products & Ongoing Clinical Trials Overview 62

Table 116: VISCO 360 Viscosurgical System-Primary Open Angle Glaucoma-Product Status 62

Table 117: VISCO 360 Viscosurgical System-Primary Open Angle Glaucoma-Product Description 62

Table 118: Sight Sciences, Inc.-Ongoing Clinical Trials Overview 63

Table 119: VISCO 360 Viscosurgical System-Primary Open Angle Glaucoma-Multi-center, Prospective, Randomized, Controlled Clinical Evaluation of the Safety and Effectiveness of the Sight Sciences VISCO360 Viscosurgical System in Canaloplasty Versus Selective Laser Trabeculoplasty in the Reduction of IOP in Primary Open Angle Glaucoma 64

Table 120: SOLX Inc Pipeline Products & Ongoing Clinical Trials Overview 65

Table 121: SOLX Gold Shunt-Product Status 65

Table 122: SOLX Gold Shunt-Product Description 65

Table 123: Tel Aviv University Pipeline Products & Ongoing Clinical Trials Overview 66

Table 124: Direct Laser Trabeculoplasty System-Product Status 66

Table 125: Direct Laser Trabeculoplasty System-Product Description 66

Table 126: Glaucoma Implant-Product Status 67

Table 127: Glaucoma Implant-Product Description 67

Table 128: TonoGuard Ltd. Pipeline Products & Ongoing Clinical Trials Overview 68

Table 129: EasyIOP-Product Status 68

Table 130: EasyIOP-Product Description 68

Table 131: University of Colorado Pipeline Products & Ongoing Clinical Trials Overview 69

Table 132: Aqueous Humor Micro-Bypass Shunt-Product Status 69

Table 133: Aqueous Humor Micro-Bypass Shunt-Product Description 69

Table 134: Glaucoma Device-Product Status 70

Table 135: Glaucoma Device-Product Description 70

Table 136: University of Michigan Pipeline Products & Ongoing Clinical Trials Overview 71

Table 137: Magnetoelastic Actuator-Product Status 71

Table 138: Magnetoelastic Actuator-Product Description 71

Table 139: University of Rostock Pipeline Products & Ongoing Clinical Trials Overview 72

Table 140: PTX-Eluting Microstent-Product Status 72

Table 141: PTX-Eluting Microstent-Product Description 72

Table 142: ViSci Ltd Pipeline Products & Ongoing Clinical Trials Overview 73

Table 143: Eye-D-Product Status 73

Table 144: Eye-D-Product Description 73

Table 145: Westhouse Medical Services Plc Pipeline Products & Ongoing Clinical Trials Overview 74

Table 146: Pneumatic Trabeculoplasty System-Product Status 74

Table 147: Pneumatic Trabeculoplasty System-Product Description 74

Table 148: Glossary 191

You can also purchase parts of this report.
Do you want to check out a section wise price list?
Get Price Break-up

Why Buy From US?

RRR
Refine Robust Result (RRR) Framework

What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story

reach
Our Reach Is Unmatched

We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.

Research
Shifting the Research Paradigm

While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.

Insite
More Insights-Better Decisions

With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.

Trust
Transparency and Trust

Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.

support
Round the Clock Support

If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.

Why Client Choose Us?

400000+ Reports in repository
150+ Consulting project a year
100+ Analysts
8000+ Client Queries in 2022